Microvascular decompression (MVD) is associated with a high incidence of postoperative nausea and vomiting (PONV). Unlike in general surgery, where PONV is predominantly serotonin-mediated, MVD additionally activates non-serotonergic emetic mechanisms, including vestibular stimulation and direct brainstem perturbation. Whether selective 5-HT₃ receptor antagonists can effectively prevent PONV in MVD remains unclear....
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change for audiology practice; this is a surgical anesthesia study relevant to neurosurgery and anesthesiology teams, not audiologists or hearing specialists.
Microvascular decompression surgery is occasionally performed for auditory or vestibular nerve conditions, so awareness of perioperative nausea management approaches may be marginally relevant to surgical audiology teams.
- 01Granisetron's efficacy for nausea prevention after microvascular decompression surgery is questioned due to non-serotonergic emetic pathways.
- 02Microvascular decompression involves brainstem-adjacent surgery where nausea risk is high.
- 03Study findings are primarily relevant to neurosurgery and anesthesiology, not audiology.
- 04Published in Cureus, a peer-reviewed but open-access journal with variable impact.
- 05No direct hearing or vestibular outcome measures are reported.
Granisetron provides prophylaxis for postoperative nausea and vomiting in microvascular decompression surgery despite prominent non-serotonergic emetic pathways.
studyunclear- PMID
- 42592144
- DOI
- 10.7759/cureus.112568.
- Journal
- Cureus
- Publication type
- research_article
- Evidence level
- 4
- Population
- Patients undergoing microvascular decompression surgery
- Intervention
- Granisetron for postoperative nausea and vomiting prophylaxis
Primary outcomes
Incidence of postoperative nausea and vomiting